PFG Investments LLC Trims Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

PFG Investments LLC trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,924 shares of the medical equipment provider’s stock after selling 164 shares during the quarter. PFG Investments LLC’s holdings in Lantheus were worth $321,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Lantheus by 5.6% in the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after buying an additional 389,828 shares during the period. Farallon Capital Management LLC increased its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after purchasing an additional 796,000 shares during the period. Westfield Capital Management Co. LP increased its holdings in Lantheus by 25.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after purchasing an additional 394,837 shares during the period. Dimensional Fund Advisors LP increased its holdings in Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after purchasing an additional 19,071 shares during the period. Finally, Swedbank AB increased its holdings in Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of Lantheus stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the sale, the director now owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,981 shares of company stock valued at $2,689,156 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 0.6 %

Lantheus stock opened at $109.38 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The stock has a market capitalization of $7.58 billion, a price-to-earnings ratio of 16.70 and a beta of 0.50. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The business has a fifty day moving average price of $107.80 and a 200-day moving average price of $93.85.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Analyst Ratings Changes

LNTH has been the topic of several research reports. B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JMP Securities reduced their price objective on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Leerink Partners raised their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.